Teva Receives Favorable Court Decision Regarding Generic Prevacid(R) SoluTab

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. District Court for the District of Delaware has issued a decision in its litigation over the Company’s Abbreviated New Drug Application (ANDA) to market its generic version of Takeda Pharmaceuticals North America, Inc.’s Prevacid® (Lansoprazole) SoluTab.

Go to Source

People who read this also read

• AngioScore Announces Favorable Results From The MASCOT Trial
  AngioScore, Inc., a developer of novel angioplasty catheters for use in the treatment of cardiovascular disease, announced today favorable clinical trial results from the MASCOT Trial, an important study evaluating the AngioSculpt® PTA Scoring Balloon Catheter for the treatment of femoro-popliteal P...
• Freedom From A Detectable Ultrasensitive Prostate-Specific Antigen At Two Years After Radical Prostatectomy Predicts A Favorable Clinical Outcome
  UroToday.com - In the online edition of Urology, Dr. Steven Chang and associates from the SEARCH database report that time to first detectable ultrasensitive PSA (uPSA) identifies men with low-risk recurrence prostate cancer (CaP). PSA doubling time (PSADT) 0.2ng/ml, this study determined whether...
• Lorus Therapeutics Announces Positive Result In Its Phase II Clinical Study Of LOR-2040 In Acute Myeloid Leukemia (AML)
  Lorus Therapeutics Inc. (TSX:LOR) ("Lorus" or the "Corporation"), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, announced that its Phase II clinical trial in refractory and relapsed AML with LOR-2040...
• Tripep: The ChronVac-C(R) Study Has Been Successfully Completed With Good Safety And Favorable Clinical Data
  All samples from the 12 patients with chronic Hepatitis C genotype 1 treated with Tripep's therapeutic vaccine ChronVac-C® have now been collected. The treatment was found to be safe, immunogenic and had transient effects on the serum levels of hepatitis C virus. This provides a proof-of-concept for...
• MethylGene Reports Favorable Phase I Data For MGCD265 In Solid Tumors At The AACR-NCI-EORTC International Conference
  MethylGene Inc. (TSX:MYG) reported preliminary Phase I data for MGCD265 in a poster session at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston. Go to Source...